Johnson & Johnson, Q2 Estimates
Digest more
Johnson, stock and Profit
Digest more
Mike Johnson calls for 'transparency' in Epstein case
Digest more
Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.
C.J. Gardner-Johnson said he "retracts" the comments he made about the Philadelphia Eagles after he was traded to the Houston Texans this offseason, when he said the team "probably won't see a ring without me.
Explore more
In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its popular immune system medicine Stelara, which is facing a patent cliff. Sales in its smaller, medtech division increased 6 per cent.
The Motley Fool. DATE Wednesday, July 16, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Joaquin DuatoChief Financial Officer — Joe WolkChief Financial Officer (transition/introduction) — Darren SnellgroveExecutive Vice President,
Johnson shared yet another personal insight that nobody asked for: His jizz has substantially more microplastics in it than his blood does. On X on Tuesday, Johnson posted: “I have microplastics in my ejaculate.
The third-term Democrat from Dallas faces long odds in a state that has only elected Republicans to statewide office for three decades.
Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.
9hon MSN
OL Masterminds, the brainchild of Johnson and O-line guru Duke Manyweather, is an annual summit for linemen who want to share tricks of the trade and learn for themselves how to up their game.